CA-SENTRY
30.11.2022 16:01:37 CET | Business Wire | Press release
Sentry, the leader in developer-first application monitoring, today announced it has acquired Codecov, the leading dedicated code coverage reporting solution, providing developers with actionable insights into their workflow. The acquisition expands Sentry’s product offering for development teams to improve code quality and velocity even earlier in the development life cycle, helping to accelerate remediation and enabling the delivery of better end-user experiences.
“Our mission has always been to empower developers to ship high quality code, faster than anyone else through context and insights, versus dashboards and tools that frankly weren’t built for resolution,” said Milin Desai, CEO of Sentry. “The Codecov team shares this singular focus – and enables us to offer developers even more comprehensive insight into their application’s code quality earlier in the development cycle.”
Codecov is the leading dedicated code coverage solution, which helps thousands of development teams at companies like Lyft, Slack, Washington Post, GoodRx, and Alteryx, confidently ship stable code. Similar to Sentry, Codecov works within developers’ existing workflows for software development, providing feedback, insight, and ownership over the quality of code regardless of platform, language, or CI/CD tooling. With the acquisition, Sentry customers will benefit from insights and protection over their code quality both pre- and post-deployment.
"At Lyft, we want to help our developers reliably ship code as fast as possible by providing an environment that allows them to feel confident to make and ship changes in code," said Jun Li, Staff Software Engineer at Lyft. "Codecov provides a source of truth for our teams. It reduces friction as it is flexible enough to fit into any language and CI/CD so engineers can see the impact and dig deeper into code changes, all in one place. The implementation of Codecov has improved the overall developer experience and we're seeing more and more adoption of it across our teams.”
“From day one, our primary focus has been on using tools like code coverage to help developers ship quickly and reliably,” said Jerrod Engelberg, CEO of Codecov. “There’s an obvious alignment between Sentry and Codecov in how we empower developers to feel confident in making and shipping changes. We are climbing the same summit of software reliability from opposite sides, and with this, our customers new and old will experience faster development cycles, quicker discovery and remediation of bugs, and an overall better developer experience. ”
Codecov providing intelligent code coverage furthers Sentry’s commitment to addressing the evolving needs of software developers who are using tooling that is not purpose-built for their workflows or their most pressing problems. The addition of Codecov, along with Sentry’s other recent investments will serve to evolve application monitoring for software developers everywhere.
Codecov’s talented and experienced team, including co-founders Jerrod Engelberg and Eli Hooten, will join the Sentry team.
Read the Sentry and Codecov blogs to learn more about how the companies will work together to bring a new level of actionable insight directly into the developer’s workflow.
About Sentry
For software teams, Sentry is essential for monitoring application code quality. From Error tracking to Performance monitoring, developers can see clearer, solve quicker, and learn continuously about their applications — from frontend to backend. Loved by more than 3.5 million developers and 85,000 organizations worldwide, Sentry provides code-level observability to many of the world’s best-known companies like Disney, Cloudflare, Eventbrite, Slack, Supercell, and Rockstar Games. Learn more at sentry.io or follow Sentry on GitHub, Twitter, Dribbble, or LinkedIn.
About Codecov
Codecov is the leading dedicated code coverage reporting solution focused on helping developers quickly ship reliable code while helping engineering teams save time and improve the overall developer experience. The company helps thousands of development teams at some of the world’s largest companies like Lyft, Slack, Washington Post, GoodRx, and Alteryx, confidently deliver stable and bug-free code with highly integrated tools to surface coverage insights where they are needed.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221129006193/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom